A carregar...
IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
IMpower132 explored the safety and efficacy of atezolizumab plus pemetrexed and platinum‐based chemotherapy as first‐line treatment for advanced non‐small‐cell lung cancer (NSCLC). Key eligibility criteria for the phase 3, open‐label, IMpower132 study included age ≥18 y, histologically or cytologica...
Na minha lista:
| Publicado no: | Cancer Sci |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8019191/ https://ncbi.nlm.nih.gov/pubmed/33462883 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14817 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|